CA2754350C - Oxyntomodulin analogs - Google Patents

Oxyntomodulin analogs Download PDF

Info

Publication number
CA2754350C
CA2754350C CA2754350A CA2754350A CA2754350C CA 2754350 C CA2754350 C CA 2754350C CA 2754350 A CA2754350 A CA 2754350A CA 2754350 A CA2754350 A CA 2754350A CA 2754350 C CA2754350 C CA 2754350C
Authority
CA
Canada
Prior art keywords
seq
peptide
residue
oxm
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2754350A
Other languages
English (en)
French (fr)
Other versions
CA2754350A1 (en
Inventor
Paul E. Carrington
George J. Eiermann
Donald J. Marsh
Joseph M. Metzger
Alessandro Pocai
Ranabir Sinha Roy
Elisabetta Bianchi
Paolo Ingallinella
Antonello Pessi
Alessia Santoprete
Elena Capito
Richard Dimarchi
Brian Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Indiana University Research and Technology Corp
Merck Sharp and Dohme LLC
Original Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Indiana University Research and Technology Corp
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto di Ricerche di Biologia Molecolare P Angeletti SpA, Indiana University Research and Technology Corp, Merck Sharp and Dohme LLC filed Critical Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Publication of CA2754350A1 publication Critical patent/CA2754350A1/en
Application granted granted Critical
Publication of CA2754350C publication Critical patent/CA2754350C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Physical Water Treatments (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2754350A 2009-02-19 2009-12-18 Oxyntomodulin analogs Expired - Fee Related CA2754350C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2009/034448 2009-02-19
PCT/US2009/034448 WO2010096052A1 (en) 2009-02-19 2009-02-19 Oxyntomodulin analogs
PCT/US2009/068678 WO2010096142A1 (en) 2009-02-19 2009-12-18 Oxyntomodulin analogs

Publications (2)

Publication Number Publication Date
CA2754350A1 CA2754350A1 (en) 2010-08-26
CA2754350C true CA2754350C (en) 2019-07-09

Family

ID=42634127

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2754350A Expired - Fee Related CA2754350C (en) 2009-02-19 2009-12-18 Oxyntomodulin analogs

Country Status (23)

Country Link
US (2) US20120165503A1 (Direct)
EP (1) EP2398483B1 (Direct)
JP (1) JP5756961B2 (Direct)
KR (1) KR101634139B1 (Direct)
CN (1) CN102573872B (Direct)
AU (1) AU2009340439B2 (Direct)
BR (1) BRPI0924307B8 (Direct)
CA (1) CA2754350C (Direct)
CL (1) CL2011002036A1 (Direct)
CY (1) CY1116917T1 (Direct)
DK (1) DK2398483T3 (Direct)
ES (1) ES2524477T3 (Direct)
HR (1) HRP20141215T1 (Direct)
IL (1) IL214729A (Direct)
MX (1) MX2011008717A (Direct)
PE (1) PE20120621A1 (Direct)
PL (1) PL2398483T3 (Direct)
PT (1) PT2398483E (Direct)
RU (1) RU2542362C2 (Direct)
SG (1) SG173791A1 (Direct)
SI (1) SI2398483T1 (Direct)
WO (2) WO2010096052A1 (Direct)
ZA (1) ZA201106051B (Direct)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2628241C (en) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
CN101578102B (zh) 2007-01-05 2013-07-17 印第安纳大学研究及科技有限公司 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
US8981047B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Glucagon antagonists
ES2558155T3 (es) 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
EP2952202B1 (en) 2008-06-17 2017-10-18 Indiana University Research and Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
CN103641907A (zh) 2008-06-17 2014-03-19 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共激动剂
CA2747499A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
SG176858A1 (en) 2009-06-16 2012-02-28 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
AR079345A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
CN102834108A (zh) 2010-01-27 2012-12-19 印第安纳大学研究及科技有限公司 用于治疗代谢紊乱和肥胖症的胰高血糖素拮抗剂-gip激动剂偶联物和组合物
SG184988A1 (en) 2010-04-27 2012-11-29 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
KR20130062931A (ko) 2010-05-13 2013-06-13 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 핵 호르몬 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
JP2013540102A (ja) 2010-06-24 2013-10-31 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション アミド結合を介して修飾されたグルカゴンスーパーファミリーのペプチドプロドラッグ
PE20140186A1 (es) 2010-12-22 2014-02-13 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
WO2012150503A2 (en) * 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
EP2707713A2 (en) * 2011-05-10 2014-03-19 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
ES2968043T3 (es) 2011-06-10 2024-05-06 Hanmi Science Co Ltd Nuevos derivados de oxintomodulina y composición farmacéutica para el tratamiento de la obesidad que comprende la misma
SI2721062T1 (sl) 2011-06-17 2019-03-29 Hanmi Science Co., Ltd. Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega
PT2723367T (pt) 2011-06-22 2017-08-11 Univ Indiana Res & Tech Corp Co-agonistas do recetor da glucagina/glp-1
WO2012177444A2 (en) 2011-06-22 2012-12-27 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2729493B1 (en) 2011-07-04 2020-06-10 IP2IPO Innovations Limited Novel compounds and their effects on feeding behaviour
JP6359972B2 (ja) 2011-11-03 2018-07-18 ジーランド ファーマ アクティーゼルスカブ Ｇｌｐ−１受容体アゴニストペプチドガストリンコンジュゲート
MX2014003579A (es) * 2011-11-17 2015-04-10 Univ Indiana Res & Tech Corp Peptidos de la superfamilia de glucagon que presentan actividad del receptor de glucocorticoide.
AU2013276610A1 (en) * 2012-06-14 2015-01-15 Sanofi Exendin-4 peptide analogues
KR20150023013A (ko) 2012-06-21 2015-03-04 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 수용체 활성을 나타내는 글루카곤 유사체
US10442847B2 (en) 2012-07-23 2019-10-15 Zealand Pharma A/S Glucagon analogues
KR101968344B1 (ko) * 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
NZ708103A (en) 2012-11-06 2018-07-27 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
CN104968674A (zh) * 2012-12-19 2015-10-07 诺和诺德股份有限公司 具有胆固醇流出活性的新颖的glp-1受体激动剂
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
CN105189465B (zh) 2013-03-21 2019-02-26 赛诺菲-安万特德国有限公司 合成含有乙内酰脲的肽产物
ES2624961T3 (es) 2013-03-21 2017-07-18 Sanofi-Aventis Deutschland Gmbh Síntesis de productos de péptido que contienen imida cíclica
WO2014161835A1 (en) 2013-04-03 2014-10-09 Sanofi Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof
ES2927607T3 (es) * 2013-09-13 2022-11-08 Scripps Research Inst Agentes terapéuticos modificados y composiciones de los mismos
EA034322B1 (ru) 2013-10-17 2020-01-28 Зилэнд Фарма А/С Ацилированные аналоги глюкагона
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
MX369770B (es) 2013-11-06 2019-11-21 Zealand Pharma As Compuestos agonistas triples de glucagón-glp-1-gip.
KR102310389B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 Ｇｉｐ-ｇｌｐ-1 이원 효능제 화합물 및 방법
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609800A (zh) 2013-12-13 2016-03-16 賽諾菲公司 做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
CN106456589B (zh) 2013-12-18 2020-07-07 斯克利普斯研究所 修饰的治疗剂、订合的肽脂质缀合物及其组合物
AR100306A1 (es) * 2014-02-18 2016-09-28 Novo Nordisk As Análogos de glucagón estables y uso para el tratamiento de la hipoglucemia
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN106519015B (zh) * 2014-09-23 2020-04-17 深圳市图微安创科技开发有限公司 胃泌酸调节素类似物
US20160114000A1 (en) 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors
DK3212218T3 (da) 2014-10-29 2021-08-30 Zealand Pharma As GIP-agonistforbindelser og fremgangsmåder
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
US11135271B2 (en) * 2014-12-30 2021-10-05 Hanmi Pharm. Co., Ltd. Glucagon derivatives with improved stability
RU2735762C2 (ru) 2015-04-16 2020-11-06 Зилэнд Фарма А/С Ацилированный аналог глюкагона, его применение и способы получения
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
UY36759A (es) 2015-06-30 2017-01-31 Hanmi Pharm Ind Co Ltd Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
WO2017062334A1 (en) 2015-10-05 2017-04-13 Merck Sharp & Dohme Corp. Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
WO2017062271A2 (en) 2015-10-06 2017-04-13 Merck Sharp & Dohme Corp. Antibody drug conjugate for anti-inflammatory applications
EP3377521A4 (en) * 2015-10-27 2019-05-01 Merck Sharp & Dohme Corp. LONG-ACTING CO AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
US10493125B2 (en) 2015-12-09 2019-12-03 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and GLP-1 receptors
WO2017116205A1 (ko) 2015-12-31 2017-07-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체
EP3407916B1 (en) 2016-01-29 2023-12-20 Merck Sharp & Dohme LLC Phosphonate linkers and their use to facilitate cellular retention of compounds
CA3029518A1 (en) 2016-06-29 2018-01-04 Hanmi Pharm. Co., Ltd. Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
CN117384274A (zh) 2016-12-09 2024-01-12 西兰制药公司 酰化的glp-1/glp-2双重激动剂
CN108299553B (zh) * 2017-01-13 2021-07-16 博瑞生物医药（苏州）股份有限公司 胃泌酸调节素修饰物
CN106986924A (zh) * 2017-03-23 2017-07-28 中国药科大学 胃泌酸调节素（oxm）类似物及其应用
AU2018318672B2 (en) * 2017-08-16 2021-04-15 Dong-A St Co., Ltd. Acylated oxyntomodulin peptide analog
MA50474A (fr) 2017-09-25 2020-09-02 Merck Sharp & Dohme Co-agonistes à action prolongée des récepteurs du glucagon et du glp-1
CN109836504B (zh) * 2017-11-24 2022-08-02 浙江道尔生物科技有限公司 一种治疗代谢疾病的多结构域活性蛋白
CN109836488B (zh) * 2017-11-24 2022-08-23 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物
WO2020098657A1 (zh) * 2018-11-12 2020-05-22 天津药物研究院有限公司 具有双重受体激动作用的胰高血糖素衍生肽及其用途
KR20210109552A (ko) 2018-12-21 2021-09-06 지앙수 헨그루이 메디슨 컴퍼니 리미티드 이중특이적 단백질
US11471512B2 (en) 2019-03-01 2022-10-18 Merck Sharp & Dohme Llc Pharmaceutical compositions of a peptide
CN110684082B (zh) * 2019-10-08 2021-12-10 江苏诺泰澳赛诺生物制药股份有限公司 Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途
EP3842449A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled olefin co-agonists of the glucagon and glp-1 receptors
EP3842061A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled triazole co-agonists of the glucagon and glp-1 receptors
EP3842060A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
KR102154959B1 (ko) * 2020-04-29 2020-09-10 동아에스티 주식회사 지속형 glp-1 및 글루카곤 수용체 이중작용제
EP4148064A4 (en) * 2020-05-09 2024-06-12 Tianjin Institute Of Pharmaceutical Research Co., Ltd. POLYPEPTIDE DERIVATIVE HAVING DUAL RECEPTOR AGONIST ACTION AND USE THEREOF
CN112898405B (zh) * 2021-01-22 2023-02-28 深圳市图微安创科技开发有限公司 多肽化合物及其在预防或治疗糖尿病或糖尿病并发症中的应用
WO2022257979A1 (en) 2021-06-09 2022-12-15 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use
CN119930789A (zh) * 2023-11-06 2025-05-06 成都奥达生物科技有限公司 一种gcg激动剂化合物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275152A (en) * 1977-02-03 1981-06-23 Eastman Kodak Company Hydrolysis of protein-bound cholesterol esters
US7238663B2 (en) * 2001-08-28 2007-07-03 Eli Lilly And Company Pre-mixes of GLP-1 and basal insulin
EP1585956A4 (en) 2001-09-24 2009-10-21 Univ Oregon Health & Science EVALUATIONS OF NEURONS IN THE ARQUE CORE FOR THE SCREENING OF AGENTS OF MODIFICATION OF FOOD BEHAVIOR
JP4733922B2 (ja) * 2002-01-10 2011-07-27 インペリアル・イノベ−ションズ・リミテッド 摂食行動の修正
AU2003239478A1 (en) * 2002-06-04 2003-12-22 Eli Lilly And Company Modified glucagon-like peptide-1 analogs
US7364875B2 (en) * 2003-10-30 2008-04-29 Cresent Innovations, Inc. Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
SI1891105T1 (sl) * 2005-06-13 2012-07-31 Imp Innovations Ltd Analogi oksintomodulina in njihovi učinki na prehranjevalno vedenje
AU2007221366B2 (en) 2006-02-22 2012-08-23 Msd Italia S.R.L. Oxyntomodulin derivatives
EP2615108B1 (en) * 2006-09-08 2016-10-26 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and thier uses
JP5231732B2 (ja) 2006-10-26 2013-07-10 株式会社東芝 冷却装置、およびこれを備えた電子機器
CA2677932A1 (en) * 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
CN103641907A (zh) 2008-06-17 2014-03-19 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共激动剂
CA2747499A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs

Also Published As

Publication number Publication date
EP2398483A1 (en) 2011-12-28
CN102573872B (zh) 2016-03-23
US20150307580A1 (en) 2015-10-29
KR101634139B1 (ko) 2016-06-28
AU2009340439B2 (en) 2015-07-16
SI2398483T1 (sl) 2015-01-30
BRPI0924307A2 (Direct) 2017-08-22
PE20120621A1 (es) 2012-06-08
CY1116917T1 (el) 2017-04-05
CN102573872A (zh) 2012-07-11
KR20120068755A (ko) 2012-06-27
EP2398483A4 (en) 2013-03-06
CA2754350A1 (en) 2010-08-26
DK2398483T3 (da) 2014-10-27
CL2011002036A1 (es) 2012-02-03
ES2524477T3 (es) 2014-12-09
MX2011008717A (es) 2012-09-28
PL2398483T3 (pl) 2015-03-31
EP2398483B1 (en) 2014-09-24
WO2010096052A1 (en) 2010-08-26
BRPI0924307B1 (pt) 2020-05-05
JP2012518035A (ja) 2012-08-09
WO2010096142A1 (en) 2010-08-26
IL214729A0 (en) 2011-11-30
JP5756961B2 (ja) 2015-07-29
HRP20141215T1 (hr) 2015-02-13
AU2009340439A1 (en) 2011-09-15
RU2011134596A (ru) 2013-03-27
HK1165333A1 (en) 2012-10-05
ZA201106051B (en) 2014-07-30
SG173791A1 (en) 2011-10-28
RU2542362C2 (ru) 2015-02-20
IL214729A (en) 2016-06-30
US20120165503A1 (en) 2012-06-28
BRPI0924307A8 (pt) 2017-12-12
PT2398483E (pt) 2014-12-04
US9593155B2 (en) 2017-03-14
BRPI0924307B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CA2754350C (en) Oxyntomodulin analogs
EP1999143B1 (en) Neuromedin u receptor agonists and uses thereof
US20110301079A1 (en) Neuromedin u receptor agonists and uses thereof
WO2011005611A1 (en) Neuromedin u receptor agonists and uses thereof
US20090104210A1 (en) Peptide compounds for treating obesity and insulin resistance
EP3359191A1 (en) Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
WO2010138343A1 (en) Neuromedin u receptor agonists
BRPI1001307B1 (pt) injeção de oxigênio em bacia de flotação do processo de remoção de substâncias poluentes em cursos d'água
HK1165333B (en) Oxyntomodulin analogs
US20100143383A1 (en) Oxgr1 agonists for use in therapies for metabolic disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141118

MKLA Lapsed

Effective date: 20211220